Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   38870   clinical trials with a EudraCT protocol, of which   6391   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study, with an Open-Label Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of E5501 in Subjects with Chronic Hepatitis C Virus Related Thrombocytopenia who are Potential Candidates for Antiviral Treatment

    Summary
    EudraCT number
    2010-024479-20
    Trial protocol
    DE   BG  
    Global end of trial date
    01 May 2014

    Results information
    Results version number
    v2(current)
    This version publication date
    25 Mar 2016
    First version publication date
    05 Aug 2015
    Other versions
    v1
    Version creation reason
    • Correction of full data set
    Results are being revised due to training issue with our staff and to reconcile the results to ensure consistency with ClinicalTrials.gov results.

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    E5501-G000-203
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01355289
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Eisai
    Sponsor organisation address
    155 Tice Boulevard, Woodcliff Lake, United States, 07677
    Public contact
    Medical Information, Eisai Limited, +44 08456761400, LmedInfo@eisai.net
    Scientific contact
    Medical Information, Eisai Limited, +44 08456761400, LmedInfo@eisai.net
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    01 May 2014
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    01 May 2014
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment
    Protection of trial subjects
    This study was conducted in accordance with standard operating procedures (SOPs) of the sponsor (or designee), which are designed to ensure adherence to Good Clinical Practice (GCP) guidelines as required by the following: - Principles of the World Medical Association Declaration of Helsinki (World Medical Association, 2008) - International Conference on Harmonisation (ICH) E6 Guideline for GCP (CPMP/ICH/135/95) of the European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, International Conference on Harmonisation of Pharmaceuticals for Human Use - Title 21 of the United States (US) Code of Federal Regulations (US 21 CFR) regarding clinical studies, including Part 50 and Part 56 concerning informed subject consent and Institutional Review Board (IRB) regulations and applicable sections of US 21 CFR Part 312 - European Good Clinical Practice Directive 2005/28/EC and Clinical Trial Directive 2001/20/EC for studies conducted within any European Union (EU) country. All suspected unexpected serious adverse reactions were reported, as required, to the Competent Authorities of all involved EU member states. - Article 14, Paragraph 3, and Article 80-2 of the Pharmaceutical Affairs Law (Law No. 145, 1960) for studies conducted in Japan, in addition to Japan’s GCP Subject Information and Informed Consent.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    10 Nov 2011
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 45
    Country: Number of subjects enrolled
    Bulgaria: 3
    Country: Number of subjects enrolled
    France: 3
    Country: Number of subjects enrolled
    Germany: 5
    Country: Number of subjects enrolled
    Israel: 9
    Worldwide total number of subjects
    65
    EEA total number of subjects
    11
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    60
    From 65 to 84 years
    5
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    The Screening Period encompassed 14 days ±7 days. Prerandomization assessments took place in all participants who had provided informed consent.

    Period 1
    Period 1 title
    Core Study
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Carer

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Placebo (Core Study)
    Arm description
    Placebo, was administered orally, once daily for up to 21 days.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Once daily.

    Arm title
    Avatrombopag 10 mg (Core Study)
    Arm description
    Avatrombopag 10 mg, was administered orally, once daily, preferably with food for up to 21 days.
    Arm type
    Active comparator

    Investigational medicinal product name
    Avatrombopag
    Investigational medicinal product code
    E5501
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    10 mg, tablet form, orally, once daily.

    Arm title
    Avatrombopag 20 mg (Core Study)
    Arm description
    Avatrombopag 20 mg, was administered orally, once daily, preferably with food for up to 21 days.
    Arm type
    Active comparator

    Investigational medicinal product name
    Avatrombopag
    Investigational medicinal product code
    E5501
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    20 mg, tablet form, orally, once daily.

    Arm title
    Avatrombopag 30 mg (Core Study)
    Arm description
    Avatrombopag 30 mg, was administered orally, once daily, preferably with food for up to 21 days.
    Arm type
    Active comparator

    Investigational medicinal product name
    Avatrombopag
    Investigational medicinal product code
    E5501
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    30 mg, tablet form, orally, once daily.

    Number of subjects in period 1
    Placebo (Core Study) Avatrombopag 10 mg (Core Study) Avatrombopag 20 mg (Core Study) Avatrombopag 30 mg (Core Study)
    Started
    17
    16
    18
    14
    Completed
    16
    16
    18
    12
    Not completed
    1
    0
    0
    2
         Not specified
    -
    -
    -
    1
         Adverse event, non-fatal
    1
    -
    -
    -
         Inadequate therapeutic effect
    -
    -
    -
    1
    Period 2
    Period 2 title
    Open Label Extension (OLE)
    Is this the baseline period?
    No
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded

    Arms
    Arm title
    Avatrombopag (Open Label Extension)
    Arm description
    Avatrombopag was initiated at a dose of 20 mg, once daily in the open label extension (OLE) period. The avatrombopag dose was titrated up or down in accordance with their individual response within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.
    Arm type
    Experimental

    Investigational medicinal product name
    Avatrombopag
    Investigational medicinal product code
    E5501
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    5-50 mg, tablet form, orally, once daily.

    Number of subjects in period 2
    Avatrombopag (Open Label Extension)
    Started
    62
    Completed
    28
    Not completed
    34
         Lack of efficacy
    29
         Not specified
    3
         Adverse event, non-fatal
    1
         Lost to follow-up
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo (Core Study)
    Reporting group description
    Placebo, was administered orally, once daily for up to 21 days.

    Reporting group title
    Avatrombopag 10 mg (Core Study)
    Reporting group description
    Avatrombopag 10 mg, was administered orally, once daily, preferably with food for up to 21 days.

    Reporting group title
    Avatrombopag 20 mg (Core Study)
    Reporting group description
    Avatrombopag 20 mg, was administered orally, once daily, preferably with food for up to 21 days.

    Reporting group title
    Avatrombopag 30 mg (Core Study)
    Reporting group description
    Avatrombopag 30 mg, was administered orally, once daily, preferably with food for up to 21 days.

    Reporting group values
    Placebo (Core Study) Avatrombopag 10 mg (Core Study) Avatrombopag 20 mg (Core Study) Avatrombopag 30 mg (Core Study) Total
    Number of subjects
    17 16 18 14 65
    Age categorical
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    0
        From 65-84 years
    0
        85 years and over
    0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    50.2 ± 7.96 55.3 ± 8.06 54.9 ± 7.38 53.6 ± 7.26 -
    Gender categorical
    Units: Subjects
        Female
    3 4 5 5 17
        Male
    14 12 13 9 48

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Placebo (Core Study)
    Reporting group description
    Placebo, was administered orally, once daily for up to 21 days.

    Reporting group title
    Avatrombopag 10 mg (Core Study)
    Reporting group description
    Avatrombopag 10 mg, was administered orally, once daily, preferably with food for up to 21 days.

    Reporting group title
    Avatrombopag 20 mg (Core Study)
    Reporting group description
    Avatrombopag 20 mg, was administered orally, once daily, preferably with food for up to 21 days.

    Reporting group title
    Avatrombopag 30 mg (Core Study)
    Reporting group description
    Avatrombopag 30 mg, was administered orally, once daily, preferably with food for up to 21 days.
    Reporting group title
    Avatrombopag (Open Label Extension)
    Reporting group description
    Avatrombopag was initiated at a dose of 20 mg, once daily in the open label extension (OLE) period. The avatrombopag dose was titrated up or down in accordance with their individual response within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.

    Subject analysis set title
    Full Analysis Set
    Subject analysis set type
    Full analysis
    Subject analysis set description
    The full analysis set was the group of randomized participants.

    Primary: Number of participants who achieved Platelet Response (greater than or equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study

    Close Top of page
    End point title
    Number of participants who achieved Platelet Response (greater than or equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study
    End point description
    A responder was defined as a participant having a platelet count of greater than or equal to 100x10^9/L by Day 21 starting from an average baseline platelet count of greater than 20 x 10^9/L to less than or equal to 70 x 10^9/L.
    End point type
    Primary
    End point timeframe
    Baseline to Day 21
    End point values
    Placebo (Core Study) Avatrombopag 10 mg (Core Study) Avatrombopag 20 mg (Core Study) Avatrombopag 30 mg (Core Study)
    Number of subjects analysed
    17
    16
    18
    14
    Units: Participants
    number (not applicable)
        Yes
    1
    6
    12
    9
        No
    16
    10
    6
    5
    Statistical analysis title
    Difference of response rate (10 mg) vs placebo
    Comparison groups
    Avatrombopag 10 mg (Core Study) v Placebo (Core Study)
    Number of subjects included in analysis
    33
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0236
    Method
    Cochran-Mantel-Haenszel
    Parameter type
    Median difference (final values)
    Point estimate
    31.62
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    5.39
         upper limit
    57.84
    Statistical analysis title
    Difference of response rate (20 mg) vs placebo
    Comparison groups
    Placebo (Core Study) v Avatrombopag 20 mg (Core Study)
    Number of subjects included in analysis
    35
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0003
    Method
    Cochran-Mantel-Haenszel
    Parameter type
    Median difference (final values)
    Point estimate
    60.78
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    36.3
         upper limit
    85.27
    Statistical analysis title
    Difference of response rate (30 mg) vs placebo
    Comparison groups
    Placebo (Core Study) v Avatrombopag 30 mg (Core Study)
    Number of subjects included in analysis
    31
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0003
    Method
    Cochran-Mantel-Haenszel
    Parameter type
    Median difference (final values)
    Point estimate
    58.4
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    30.92
         upper limit
    85.88

    Secondary: Change from Baseline of Local Platelet Count by Visit during Treatment Period A1 of Core Study

    Close Top of page
    End point title
    Change from Baseline of Local Platelet Count by Visit during Treatment Period A1 of Core Study
    End point description
    Missing platelet counts were imputed using last observation carried forward (LOCF) approach for subjects who achieved platelet response at prior visits.
    End point type
    Secondary
    End point timeframe
    Day 7 and Day 14
    End point values
    Placebo (Core Study) Avatrombopag 10 mg (Core Study) Avatrombopag 20 mg (Core Study) Avatrombopag 30 mg (Core Study)
    Number of subjects analysed
    17
    16
    18
    14
    Units: x10^9/L
    arithmetic mean (standard deviation)
        Day 7
    -0.1 ± 7.15
    19.8 ± 17.59
    26.5 ± 22.06
    30.9 ± 37.65
        Day 14
    -0.2 ± 13.79
    29.2 ± 18.32
    57.2 ± 31.39
    55.4 ± 37.47
    No statistical analyses for this end point

    Secondary: Number of Participants who achieved Platelet Count greater than 30 X 10^9/L from Baseline to Day 21 during Treatment Period A1 of Core Study

    Close Top of page
    End point title
    Number of Participants who achieved Platelet Count greater than 30 X 10^9/L from Baseline to Day 21 during Treatment Period A1 of Core Study
    End point description
    Blood draws were taken to monitor platelet counts.
    End point type
    Secondary
    End point timeframe
    Baseline to Day 21
    End point values
    Placebo (Core Study) Avatrombopag 10 mg (Core Study) Avatrombopag 20 mg (Core Study) Avatrombopag 30 mg (Core Study)
    Number of subjects analysed
    17
    16
    18
    14
    Units: Participants
    number (not applicable)
        Yes
    1
    9
    16
    11
        No
    16
    7
    2
    3
    No statistical analyses for this end point

    Secondary: Number of Participants Who Initiated Antiviral Treatment by Day 21 of Period A1 of Core Study

    Close Top of page
    End point title
    Number of Participants Who Initiated Antiviral Treatment by Day 21 of Period A1 of Core Study
    End point description
    Blood draws were taken to monitor platelet counts during the first 21 days of study treatment. When a platelet count of greater than or equal to 100 X 10^9/L was attained, antiviral treatment was initiated.
    End point type
    Secondary
    End point timeframe
    Baseline to Day 21
    End point values
    Placebo (Core Study) Avatrombopag 10 mg (Core Study) Avatrombopag 20 mg (Core Study) Avatrombopag 30 mg (Core Study)
    Number of subjects analysed
    17
    16
    18
    14
    Units: Participants
    number (not applicable)
        Yes
    1
    6
    13
    9
        No
    16
    10
    5
    5
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    For each participant, treatment emergent adverse events were collected from the first day of administration of study drug up to 30 days after the last dose of study drug or up to approximately 2.5 years.
    Adverse event reporting additional description
    Safety Analysis Set was used which combines data of the Core and Extension Phase and includes subjects who had at least 1 dose of avatrombopag. Placebo treatment arm was excluded since not part of study design for the Extension Phase.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    16.0
    Reporting groups
    Reporting group title
    Avatrombopag (Open Label Extension)
    Reporting group description
    During the core study, participants were administered a fixed dose of Avatrombopag 10mg, 20mg, or 30mg,orally, once daily, preferably with food for upto 21 days. The participants initiated Open label extension with Avontrombopag 20 mg, once daily. The avotrambopag dose was titrated up or down in accordance with their individual response, within the range of a minimum of 5mg and a maximum of 50 mg for up to 48 weeks.

    Reporting group title
    Placebo (Core Study)
    Reporting group description
    Placebo, was given orally for up to 21 days once daily.

    Reporting group title
    Avatrombopag 10 mg (Core Study)
    Reporting group description
    Avatrombopag 10 mg, was administered orally, once daily, preferably with food for up to 21 days.

    Reporting group title
    Avatrombopag 20 mg (Core Study)
    Reporting group description
    Avatrombopag 20 mg, was administered orally, once daily, preferably with food for up to 21 days.

    Reporting group title
    Avatrombopag 30 mg (Core Study)
    Reporting group description
    Avatrombopag 30 mg, was administered orally, once daily, preferably with food for up to 21 days.

    Serious adverse events
    Avatrombopag (Open Label Extension) Placebo (Core Study) Avatrombopag 10 mg (Core Study) Avatrombopag 20 mg (Core Study) Avatrombopag 30 mg (Core Study)
    Total subjects affected by serious adverse events
         subjects affected / exposed
    13 / 64 (20.31%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         number of deaths (all causes)
    1
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    2 / 64 (3.13%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Leukopenia
         subjects affected / exposed
    1 / 64 (1.56%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenia
         subjects affected / exposed
    2 / 64 (3.13%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancytopenia
         subjects affected / exposed
    1 / 64 (1.56%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    2 / 64 (3.13%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Paraesthesia
         subjects affected / exposed
    1 / 64 (1.56%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    1 / 64 (1.56%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Haematuria
         subjects affected / exposed
    1 / 64 (1.56%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal failure acute
         subjects affected / exposed
    1 / 64 (1.56%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Hepatic mass
         subjects affected / exposed
    1 / 64 (1.56%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hyperglycaemia
         subjects affected / exposed
    1 / 64 (1.56%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperuricaemia
         subjects affected / exposed
    1 / 64 (1.56%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Gastroenteritis
         subjects affected / exposed
    1 / 64 (1.56%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    1 / 64 (1.56%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Avatrombopag (Open Label Extension) Placebo (Core Study) Avatrombopag 10 mg (Core Study) Avatrombopag 20 mg (Core Study) Avatrombopag 30 mg (Core Study)
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    55 / 64 (85.94%)
    6 / 17 (35.29%)
    11 / 16 (68.75%)
    12 / 18 (66.67%)
    11 / 14 (78.57%)
    Vascular disorders
    Hot flush
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Pallor
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    8 / 64 (12.50%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    2 / 18 (11.11%)
    1 / 14 (7.14%)
         occurrences all number
    9
    0
    2
    2
    1
    Chills
         subjects affected / exposed
    13 / 64 (20.31%)
    1 / 17 (5.88%)
    3 / 16 (18.75%)
    3 / 18 (16.67%)
    1 / 14 (7.14%)
         occurrences all number
    14
    1
    3
    3
    2
    Fatigue
         subjects affected / exposed
    16 / 64 (25.00%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    3 / 18 (16.67%)
    2 / 14 (14.29%)
         occurrences all number
    17
    0
    1
    4
    2
    Influenza like illness
         subjects affected / exposed
    11 / 64 (17.19%)
    2 / 17 (11.76%)
    1 / 16 (6.25%)
    4 / 18 (22.22%)
    3 / 14 (21.43%)
         occurrences all number
    13
    2
    1
    4
    3
    Injection site erythema
         subjects affected / exposed
    6 / 64 (9.38%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    7
    0
    1
    1
    0
    Irritability
         subjects affected / exposed
    7 / 64 (10.94%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    1 / 14 (7.14%)
         occurrences all number
    7
    0
    0
    1
    1
    Oedema peripheral
         subjects affected / exposed
    6 / 64 (9.38%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    6
    0
    0
    1
    0
    Pyrexia
         subjects affected / exposed
    9 / 64 (14.06%)
    1 / 17 (5.88%)
    0 / 16 (0.00%)
    2 / 18 (11.11%)
    2 / 14 (14.29%)
         occurrences all number
    13
    1
    0
    2
    2
    Chest discomfort
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Feeling cold
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Feeling of body temperature change
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1
    Injection site pruritus
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Pain
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Psychiatric disorders
    Depression
         subjects affected / exposed
    5 / 64 (7.81%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    6
    0
    0
    0
    1
    Insomnia
         subjects affected / exposed
    13 / 64 (20.31%)
    1 / 17 (5.88%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    3 / 14 (21.43%)
         occurrences all number
    13
    1
    1
    0
    3
    Anxiety
         subjects affected / exposed
    0 / 64 (0.00%)
    1 / 17 (5.88%)
    1 / 16 (6.25%)
    1 / 18 (5.56%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    1
    1
    1
    Food aversion
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    Mood altered
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    2
    Sleep disorder
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Reproductive system and breast disorders
    Spontaneous penile erection
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Injury, poisoning and procedural complications
    Burns first degree
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Tooth fracture
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1
    Investigations
    Staphylococcus test positive
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Weight decreased
         subjects affected / exposed
    0 / 64 (0.00%)
    1 / 17 (5.88%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    Cardiac disorders
    Palpitations
         subjects affected / exposed
    0 / 64 (0.00%)
    1 / 17 (5.88%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    Tachycardia
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1
    Congenital, familial and genetic disorders
    Congenital lymphoedema
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    21 / 64 (32.81%)
    0 / 17 (0.00%)
    2 / 16 (12.50%)
    2 / 18 (11.11%)
    1 / 14 (7.14%)
         occurrences all number
    26
    0
    3
    2
    1
    Leukopenia
         subjects affected / exposed
    14 / 64 (21.88%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    3 / 18 (16.67%)
    1 / 14 (7.14%)
         occurrences all number
    14
    0
    2
    3
    1
    Lymphopenia
         subjects affected / exposed
    5 / 64 (7.81%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    6
    0
    0
    0
    1
    Neutropenia
         subjects affected / exposed
    20 / 64 (31.25%)
    0 / 17 (0.00%)
    2 / 16 (12.50%)
    4 / 18 (22.22%)
    2 / 14 (14.29%)
         occurrences all number
    24
    0
    2
    4
    2
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    9 / 64 (14.06%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    2 / 18 (11.11%)
    3 / 14 (21.43%)
         occurrences all number
    10
    0
    0
    2
    3
    Dyspnoea
         subjects affected / exposed
    4 / 64 (6.25%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    2 / 18 (11.11%)
    0 / 14 (0.00%)
         occurrences all number
    4
    0
    0
    2
    0
    Dyspnoea exertional
         subjects affected / exposed
    4 / 64 (6.25%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    1 / 18 (5.56%)
    1 / 14 (7.14%)
         occurrences all number
    5
    0
    1
    1
    1
    Epistaxis
         subjects affected / exposed
    6 / 64 (9.38%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    7
    0
    1
    0
    2
    Productive cough
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    1
    1
    Respiratory tract congestion
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Upper-airway cough syndrome
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    4 / 64 (6.25%)
    1 / 17 (5.88%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    4
    1
    0
    0
    1
    Headache
         subjects affected / exposed
    12 / 64 (18.75%)
    1 / 17 (5.88%)
    0 / 16 (0.00%)
    3 / 18 (16.67%)
    2 / 14 (14.29%)
         occurrences all number
    16
    1
    0
    3
    3
    Disturbance in attention
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Dysgeusia
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1
    Hypoaesthesia
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    1
    1
    Mental impairment
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1
    Sciatica
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1
    Somnolence
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Syncope
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    6 / 64 (9.38%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    6
    0
    0
    0
    0
    Abdominal pain upper
         subjects affected / exposed
    5 / 64 (7.81%)
    1 / 17 (5.88%)
    1 / 16 (6.25%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    5
    1
    1
    1
    0
    Ascites
         subjects affected / exposed
    6 / 64 (9.38%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    6
    0
    0
    0
    1
    Diarrhoea
         subjects affected / exposed
    11 / 64 (17.19%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    2 / 18 (11.11%)
    2 / 14 (14.29%)
         occurrences all number
    12
    0
    1
    2
    2
    Dyspepsia
         subjects affected / exposed
    4 / 64 (6.25%)
    0 / 17 (0.00%)
    2 / 16 (12.50%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    4
    0
    2
    0
    0
    Haemorrhoids
         subjects affected / exposed
    4 / 64 (6.25%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    1 / 14 (7.14%)
         occurrences all number
    6
    0
    0
    1
    1
    Nausea
         subjects affected / exposed
    20 / 64 (31.25%)
    0 / 17 (0.00%)
    3 / 16 (18.75%)
    4 / 18 (22.22%)
    2 / 14 (14.29%)
         occurrences all number
    22
    0
    3
    4
    2
    Vomiting
         subjects affected / exposed
    8 / 64 (12.50%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    10
    0
    0
    1
    0
    Abdominal distension
         subjects affected / exposed
    0 / 64 (0.00%)
    1 / 17 (5.88%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    Anal pruritus
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    2 / 18 (11.11%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    Aphthous stomatitis
         subjects affected / exposed
    0 / 64 (0.00%)
    1 / 17 (5.88%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    Constipation
         subjects affected / exposed
    0 / 64 (0.00%)
    1 / 17 (5.88%)
    1 / 16 (6.25%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    1
    1
    0
    Flatulence
         subjects affected / exposed
    0 / 64 (0.00%)
    1 / 17 (5.88%)
    1 / 16 (6.25%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    1
    1
    0
    Proctalgia
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Renal and urinary disorders
    Haematuria
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Hepatobiliary disorders
    Liver tenderness
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    1 / 16 (6.25%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Skin and subcutaneous tissue disorders
    Pruritus
         subjects affected / exposed
    15 / 64 (23.44%)
    0 / 17 (0.00%)
    4 / 16 (25.00%)
    0 / 18 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    15
    0
    4
    0
    2
    Rash
         subjects affected / exposed
    12 / 64 (18.75%)
    2 / 17 (11.76%)
    1 / 16 (6.25%)
    2 / 18 (11.11%)
    1 / 14 (7.14%)
         occurrences all number
    14
    2
    1
    2
    1
    Rash macular
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    2
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1
    Muscle tightness
         subjects affected / exposed
    0 / 64 (0.00%)
    1 / 17 (5.88%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    Muscular weakness
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1
    Metabolism and nutrition disorders
    Hyperuricaemia
         subjects affected / exposed
    4 / 64 (6.25%)
    1 / 17 (5.88%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    1 / 14 (7.14%)
         occurrences all number
    5
    1
    0
    1
    1
    Hypertriglyceridaemia
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Hypokalaemia
         subjects affected / exposed
    0 / 64 (0.00%)
    1 / 17 (5.88%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    Infections and infestations
    Nasopharyngitis
         subjects affected / exposed
    4 / 64 (6.25%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    1 / 18 (5.56%)
    1 / 14 (7.14%)
         occurrences all number
    4
    0
    0
    1
    1
    Upper respiratory tract infection
         subjects affected / exposed
    4 / 64 (6.25%)
    0 / 17 (0.00%)
    2 / 16 (12.50%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    5
    0
    2
    0
    1
    Abscess limb
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1
    Cellulitis
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1
    Gastroenteritis
         subjects affected / exposed
    0 / 64 (0.00%)
    0 / 17 (0.00%)
    0 / 16 (0.00%)
    0 / 18 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA